Background and purpose:urokinase-typeplasminoogen activator receptor(uPAR) plays important roles in terms of fibrolysis in tissue,cell adhering prolifration and signal transduction uPAR can the detected in both cancer and matrix cells.It has been reorted that uPAR is associated with invasion and metastasis of cancer cells.This paper is to study the effects of the gene expression of uPAR and VEGF-C on onco-genesis and progression of ovarian cancer.Methods:The expression of uPAR gene protein and VEGF-C were examined immunohistochemically in 58 cases of ovarian serous cystadenocarcinoma,10 cases of borderline serous cystadenomas and 13 cases of serous cystadenocarcinoma.The relationships between the results and pathological features were studied.Results:① The expressions of uPAR in benign and malignant tumors were different significantly(P

Objective To investigate the reasons of upgrade pathologic diagnosis after cervical operation of LEEP and the principal of treatment.Methods 101 cases of clinical data with upgrade pathological diagnosis after LEEP in our hospital during september 2005 to May 2008 were analyzed retrospectively.Results 13 cases were diagnosed as cervical intraepithelial neoplasia(CIN)Ⅰ-Ⅲ while they were considered as chronic cervicitis pre-operation.60 cases of upgrade CIN and 10 cases of in-situ cervical cancer and 10 cases of early infiltration cervical cancer and 8 cases of infiltration cervical cancer were diagnosed while they were considers as CIN Ⅰ-Ⅲ before LEEP.Among the 101 cases.34 cases were re-treated.10 cases diagnosis were the same pathological diagnosis as before,14 cases diagnosis were downgrade and 10 cases were negative.There was no upgrade pathologic diagnosis.The cutting edges were negative.And lymphatic metastasis took place in 2 cases with infiltrating cervical cancer.Conclusion The malignant ratio of patients with upgrade pathology was high.We should pay attention to the patients with upgrade pathological diagnosis after LEEP.The possible treatment should be given to them according to their age,demands of breeding,chnieal stages and types of pathologic stages.

Objective The aim of this study was to investigate the clinical value of human serum Kallikrein 6 for the diagnosis and monitor of pithelial ovarian cancer. Methods Serum levels of KLK6 were analyzed with ELISA in 30 cases of epithelial ovarian carcinoma, 20 cases of benign ovarian tumor and 30 cases of healthy women. In the meantime, serum CAi25 was determined with chemiluminescence. Furthermore, serum levels of KLK6 and CA125 were also detected in 12 case of epithelial ovarian carcinoma with the same methods one week and the 3rd month postoperation of follow-up. Results Serum levels of KLK6 in epithelial ovarian carcinoma was higher than that in benign ovarian tumor and healthy women (P < 0.05). KLK6 also showed positive correlation with clinical stage, cytological grade, pelvic lymph node metastasis, recurrent or dead disease (P < 0. 05). On the contrary, KLK6 showed no significant correlation with pathological types (P >0. 05). After surgery of follow-up, KLK6 and CA125 were significantly decreased in 12 case of epithelial ovarian carcinoma (P < 0. 05). Furthermore, the total sensitivity and specificity of KLK6 in the diagnosis of epithelial ovarian carcinoma was 73.3% and 85.0% respectively, followed by the sensitivity to be 50. 0% and 88. 9% for the diagnosis of stage Ⅰ-Ⅱand Ⅲ-Ⅳ disease. Conclusion Our resuits showed KLK6 may be one of the reliable indexes for the diagnosis and monitor of ovarian cancer.